| abstract |
The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8 + cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and thus suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention provide methods for treating cancer by administering to a patient an effective amount of a DKK2 gene depleting substance, anti-tumor immunity and anti-tumor angiogenesis in a subject. It relates to a method for providing, a method for stimulating a T cell-mediated immune response against a cell population or tissue, and a method for inhibiting tumor angiogenesis in a subject. Furthermore, the present invention includes methods for diagnosing a predisposition to develop cancer or cancer or metastasis, and methods for determining the use of immunotherapy treatments or cancer vaccines to treat cancer. Furthermore, the present invention includes pharmaceutical compositions for treating cancer, as well as kits for performing the above methods. |